Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 18/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12659853 | 0.94 | ADORA2A (0.50) | ADORA2AADORA1PTGS2 | |
| SCHEMBL1885590 | 0.94 | ADORA2A (0.55) | ADORA2AADORA1 | |
| SCHEMBL12659818 | 0.92 | ADORA2A (0.51) | ADORA2AADORA1ALOX5 | |
| SCHEMBL1887563 | 0.91 | ADORA2A (0.47) | ADORA2AADORA1PTGS2 | |
| SCHEMBL12659812 | 0.89 | ADORA2A (0.45) | ADORA2AADORA1ALOX5 | |
| SCHEMBL6857591 | 0.84 | ADORA1 (0.65) | ADORA2AADORA1 | |
| SCHEMBL1882224 | 0.79 | ADORA2A (0.63) | ADORA2AADORA1 | |
| SCHEMBL1881060 | 0.79 | ADORA1 (0.57) | ADORA2AADORA1 | |
| SCHEMBL1880456 | 0.77 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL1881088 | 0.76 | ADORA2A (0.77) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105494-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105494-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105494-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105494-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA1 4/4885PTGS2 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.